Table 2.
Factors associated with response to peginterferon alfa-2b and ribavirin therapy.
| SVR | (Range or %) | Non-SVR | (Range or %) | P value | |
|---|---|---|---|---|---|
| Total | 74 | 26 | |||
| Age (y.o.) | 57 | (24–72) | 57 | (31–78) | NS |
| Sex (%) | |||||
| Male | 33 | (45) | 13 | (50) | |
| Female | 41 | (55) | 13 | (50) | NS |
| BMI (kg/m2) | 23.1 | (15.4–30.9) | 21.0 | (18.4–26.0) | NS |
| WBC (/μL) | 5100 | (2100–9730) | 5145 | (3000–8300) | NS |
| Hemoglobin (g/dL) | 14.1 | (10–16) | 14.0 | (10–16) | NS |
| Platelet (104/μL) | 21.7 | (6.9–26.5) | 11.5 | (7.3–21.1) | NS |
| AST (IU/L) | 39 | (17–377) | 44 | (17–140) | NS |
| ALT (IU/L) | 51 | (11–751) | 53 | (14–169) | NS |
| TC (mg/dL) | 183 | (106–269) | 163 | (127–248) | NS |
| <177 mg/dL (%) | 31 | (42) | 19 | (73) | |
| ≥177 mg/dL (%) | 43 | (58) | 7 | (27) | 0.005 |
| TG (mg/dL) | 98 | (56–262) | 83 | (74–176) | NS |
| <88 mg/dL (%) | 33 | (44) | 17 | (67) | |
| ≥88 mg/dL (%) | 41 | (56) | 9 | (33) | NS |
| LDL-C (mg/dL) | 109 | (30–167) | 88 | (64–117) | 0.015 |
| <98 mg/dL (%) | 30 | (40) | 20 | (77) | |
| ≥98 mg/dL (%) | 44 | (60) | 6 | (23) | 0.020 |
| HCV RNA (KIU/mL) | 1000 | (20–40900) | 1850 | (37–24200) | NS |
| Distribution of stage of fibrosis (%) | |||||
| 1 | 31 | (42) | 12 | (46) | |
| 2 | 14 | (19) | 3 | (12) | |
| 3 | 6 | (8) | 5 | (19) | |
| 4 | 3 | (4) | 1 | (4) | |
| Unknown | 20 | (27) | 5 | (19) | NS |
| Distribution of grade of inflammation (%) | |||||
| 1 | 27 | (36) | 12 | (46) | |
| 2 | 25 | (34) | 9 | (35) | |
| 3 | 2 | (3) | 0 | (0) | |
| Unknown | 20 | (27) | 5 | (19) | NS |
Data are median (range) or frequency (%).